A new marching order for the T cell army in the attack of AML
A recent publication from the Olweus group entitled "A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo" is profiled in ACIR.
First author Eirini Giannakopoulou and lead author Johanna Olweus. Photo: Fridtjof Lund-Johansen
The weekly digest in ACIR Oct 18 focuses on the recent paper by Giannakopoulou et al that demonstrates therapeutic potential of a FLT3 specific TCR for acute myeloid leukemia (AML), and includes an interview with first author Eirini Giannakopoulou and lead author Johanna Olweus.
ACIR (Accelerating Cancer Immunotherapy Research) is a web source providing a weekly synopsis of the key advances in the field of Cancer Immunotherapy research to make it easier for scientists and physicians to stay updated in a rapidly moving field.
Read the story
Original publication: Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DWL, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SEW, Woll PS, Olweus J. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nat Cancer. 2023 Oct 2.
Published Oct. 24, 2023 9:20 AM
- Last modified Apr. 5, 2024 2:52 PM
